Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology

 Fulcrum Therapeutics, Inc.^® (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has entered into a worldwide, exclusive license agreement with CAMP4 Therapeutics Corp., whereby Fulcrum will advance the discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia (DBA).

DBA is a congenital, rare blood disorder that affects an estimated 5,000 individuals worldwide. DBA is caused by genetic mutations in ribosomal subunits that halt red blood cell maturation and lead to anemia. Patients are usually diagnosed in infancy with the presentation of severe anemia and potential developmental abnormalities. Patients with DBA require lifelong management with corticosteroids and blood transfusions that are known for their toxicities and long-term complications.  

https://www.biospace.com/article/releases/fulcrum-therapeutics-signs-exclusive-global-license-agreement-in-rare-hematologycamp4-therapeutics-grants-exclusive-rights-to-advance-novel-therapies-for-diamond-blackfan-anemia/